132 related articles for article (PubMed ID: 16896016)
1. Prevalence and treatment of metabolic syndrome in adolescents with type 2 diabetes.
Sanders BH; Lubsch LM; West DS
Ann Pharmacother; 2006 Sep; 40(9):1517-21. PubMed ID: 16896016
[TBL] [Abstract][Full Text] [Related]
2. Effects of lifestyle intervention and metformin on weight management and markers of metabolic syndrome in obese adolescents.
Harden KA; Cowan PA; Velasquez-Mieyer P; Patton SB
J Am Acad Nurse Pract; 2007 Jul; 19(7):368-77. PubMed ID: 17680902
[TBL] [Abstract][Full Text] [Related]
3. All-cause mortality risk predictors in a preventive cardiology clinic cohort-examining diabetes and individual metabolic syndrome criteria: a PRECIS database study.
Doshi KB; Kashyap SR; Brennan DM; Hoar BM; Cho L; Hoogwerf BJ
Diabetes Obes Metab; 2009 Feb; 11(2):102-8. PubMed ID: 18494803
[TBL] [Abstract][Full Text] [Related]
4. Reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering: a role for fenofibrate. Introduction.
Sacks FM
Am J Cardiol; 2008 Dec; 102(12A):1L-3L. PubMed ID: 19084082
[No Abstract] [Full Text] [Related]
5. Normalization of metabolic syndrome using fenofibrate, metformin or their combination.
Nieuwdorp M; Stroes ES; Kastelein JJ;
Diabetes Obes Metab; 2007 Nov; 9(6):869-78. PubMed ID: 17924869
[TBL] [Abstract][Full Text] [Related]
6. Type 2 diabetes in children and adolescents--the next epidemic?
Vivian EM
Curr Med Res Opin; 2006 Feb; 22(2):297-306. PubMed ID: 16466601
[TBL] [Abstract][Full Text] [Related]
7. The metabolic syndrome among postmenopausal women in Ecuador.
Hidalgo LA; Chedraui PA; Morocho N; Alvarado M; Chavez D; Huc A
Gynecol Endocrinol; 2006 Aug; 22(8):447-54. PubMed ID: 17012107
[TBL] [Abstract][Full Text] [Related]
8. Management of metabolic syndrome in children and adolescents.
Pacifico L; Anania C; Martino F; Poggiogalle E; Chiarelli F; Arca M; Chiesa C
Nutr Metab Cardiovasc Dis; 2011 Jun; 21(6):455-66. PubMed ID: 21565479
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A
Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343
[TBL] [Abstract][Full Text] [Related]
10. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents.
McIntyre RS; Jerrell JM
Arch Pediatr Adolesc Med; 2008 Oct; 162(10):929-35. PubMed ID: 18838645
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the Strong Heart Study.
de Simone G; Devereux RB; Chinali M; Best LG; Lee ET; Galloway JM; Resnick HE;
Diabetes Care; 2007 Jul; 30(7):1851-6. PubMed ID: 17440172
[TBL] [Abstract][Full Text] [Related]
12. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Black HR; Davis B; Barzilay J; Nwachuku C; Baimbridge C; Marginean H; Wright JT; Basile J; Wong ND; Whelton P; Dart RA; Thadani U;
Diabetes Care; 2008 Feb; 31(2):353-60. PubMed ID: 18000186
[TBL] [Abstract][Full Text] [Related]
13. Utilization patterns and medication adherence in patients with type 2 diabetes: variations based on type of pharmacy (chain vs independent).
Kalsekar I; Sheehan C; Peak A
Res Social Adm Pharm; 2007 Dec; 3(4):378-91. PubMed ID: 18082874
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and treatment of dyslipidemia in Canadian primary care: a retrospective cohort analysis.
Petrella RJ; Merikle E; Jones J
Clin Ther; 2007 Apr; 29(4):742-50. PubMed ID: 17617298
[TBL] [Abstract][Full Text] [Related]
15. Effect of metabolic syndrome or type II diabetes mellitus on the occurrence of recurrent vascular events in hypertensive patients.
Vlek AL; van der Graaf Y; Spiering W; Visseren FL;
J Hum Hypertens; 2008 May; 22(5):358-65. PubMed ID: 18273039
[TBL] [Abstract][Full Text] [Related]
16. Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardiometabolic Risk Profile in Patients with hypertension disease survey.
Kjeldsen SE; Naditch-Brule L; Perlini S; Zidek W; Farsang C
J Hypertens; 2008 Oct; 26(10):2064-70. PubMed ID: 18806632
[TBL] [Abstract][Full Text] [Related]
17. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
Jones PH
Am J Cardiol; 2008 Dec; 102(12A):41L-47L. PubMed ID: 19084089
[TBL] [Abstract][Full Text] [Related]
18. [Cardiometabolic high risk patients with abdominal obesity. Frequency and risk factor profile in primary care].
Scholze J; Lilienthal W; Bramlage P
MMW Fortschr Med; 2007 Sep; 149 Suppl 3():103-10. PubMed ID: 17955787
[TBL] [Abstract][Full Text] [Related]
19. Diffusion into use of exenatide for glucose control in diabetes mellitus: a retrospective cohort study of a new therapy.
Segal JB; Dy SM; Millman EA; Herbert R; Bass EB; Wu A
Clin Ther; 2007 Aug; 29(8):1784-94. PubMed ID: 17919559
[TBL] [Abstract][Full Text] [Related]
20. Clinical pictures of type 2 diabetes in Thai children and adolescents is highly related to features of metabolic syndrome.
Likitmaskul S; Santiprabhob J; Sawathiparnich P; Numbenjapon N; Chaichanwatanakul K
J Med Assoc Thai; 2005 Nov; 88 Suppl 8():S169-75. PubMed ID: 16856438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
